Trinity Biotech plc (TRIB)

Trinity Biotech plc is an Ireland-based life sciences company whose depositary receipt trades on NASDAQ under the TRIB symbol. The company, through its subsidiaries, develops, manufactures, acquires, and markets medical diagnostic products for clinical laboratories and point-of-care testing across the Americas, Asia, Africa, and Europe. Its portfolio includes tests and instrumentation used to detect infectious diseases, sexually transmitted diseases such as syphilis and herpes, SARS-CoV-2, and several viral pathogens including Epstein-Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. It also provides products for HbA1c testing in diabetes monitoring and risk assessment, as well as laboratory testing services for autoimmune and related conditions such as Sjogren’s syndrome, celiac disease, lupus, rheumatoid arthritis, and systemic sclerosis. Additional offerings span immunofluorescence, ELISA, western blot, and line immunoassay formats, along with reagent products used in the diagnosis of liver and kidney diseases and haemolytic anaemia. Trinity Biotech serves public health authorities, clinical laboratories, and reference laboratories through direct sales, distributors, and strategic partners.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.